The Native Antigen Company (now part of LGC Clinical Diagnostics) has announced the introduction of a range of veterinary reagents. The offering includes more than 90 native and recombinant antigens, and monoclonal and polyclonal antibodies for a range of viral, bacterial and protozoal veterinary diseases, to be used in the development of diagnostics and vaccines.
The company’s reagents have been developed for both livestock and companion animals, such as dogs, cats and pigs, and include a range of clinically relevant pathogens, such as coronaviruses, Borrelia, Rift Valley fever virus, African swine fever virus, Toxocara and heartworm. Suitable for a wide range of applications, these reagents can be used in research, as well as the development of immunoassays for diagnostic and vaccine R&D. The company is continuing to expand its veterinary range and is well-positioned to respond to emerging health threats.
Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “With a growing appreciation of One Health and the relationship between zoonotic human and animal diseases, The Native Antigen Company aims to support the development of much-needed diagnostics and vaccines to endemic and emerging veterinary pathogens. This marks the company’s first move into the veterinary reagent market, which we expect to grow rapidly over the coming years.”
